The Global Overactive Bladder (OAB) Therapeutics Market size is projected to reach USD 1.6 billion by 2028. The OAB market has been dominated by the US and European markets since 2015, owing to their high prevalence of urinary incontinence among patients and increasing awareness about treatments for it. It is also anticipated that the Asia Pacific region will experience exponential growth in the coming years due to its large population base and improving healthcare infrastructure.
An overactive bladder (OAB) is a urinary disorder in which the muscles that control urination are too active. OAB symptoms may include an urgent need to go, leakage of urine, and wetting accidents outside of the toilet or during sleep. Overactive bladder treatments can help manage these symptoms with medication and devices like catheters and alarms.
On the basis of Types, the market is segmented into anticholinergic agents and beta-3 adrenoreceptor agonists.
Anticholinergic agents are medications that block the action of acetylcholine, a neurotransmitter found in nerve cells. These drugs work by making it harder for muscles around the bladder neck to contract and relax. Anticholinergic agents help patients with overactive bladders control their urinary frequency and urgency symptoms.
beta-adrenoreceptor agonists are a group of medications that help relax the muscles around the bladder neck, which can make it easier for patients to control their urinary frequency and urgency symptoms. beta-adrenoreceptor agonists work by stimulating beta receptors in response to nerve signals sent from the brain. These drugs increase blood flow into the cells lining the bladder wall, making them less sensitive so they do not contract quite as much when stimulated.
On the basis of Application, the market is segmented into hospitals and clinics.
In hospitals, beta-adrenoreceptor agonists can be used in the treatment of postoperative urinary retention. These drugs are widely regarded as an important part of a multidisciplinary approach to managing patients with upper urinary tract obstruction (UTO).
beta-adrenoreceptor agonists have also been shown to reduce catheterization frequency by over 30% and increase spontaneous voiding rates. This is especially useful for elderly or frail populations who would otherwise require frequent bladder emptying procedures that pose risks such as urethral injury.
Clinics may use anticholinergic agents to help manage patients with overactive bladder, although these drugs are not recommended as monotherapy. Anticholinergics act by blocking the transmission of a neurotransmitter called acetylcholine from one neuron to another in the body. This blocks several functions such as urine flow and sphincter muscle contraction.
On the basis of Region, the market is segmented into North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa.
North America dominates in terms of the number of patients suffering from Overactive Bladder (OAB). This region has been driven by technological advancements in the healthcare sector as well as increasing awareness about health issues like chronic diseases among people
Latin America is expected to grow at the fastest rate in this market during 2021-2028. This growth can be attributed to increasing awareness about chronic diseases and its managements, rising healthcare expenditure as well as lack of competition from generic drug manufacturers which has made them comparatively inexpensive than branded counterparts in the region.
-The increasing prevalence of bladder-related disorders associated with aging coupled with improved awareness about the management of these conditions will drive growth in this market.
-Increasing incidence rates and prevalence of chronic diseases such as diabetes, obesity, arthritis among others which are often accompanied by OAB symptoms can be a major driver for this market from 2021 to 2028.
-Technological advancements are expected to help increase the adoption rate for new treatment modalities thereby driving growth in this segment. Innovations in PET scan technology have led to faster diagnosis of various cancers including those affecting urinary tract organs like prostate cancer that was once difficult to detect whereas MRI scanners have helped improve the delivery of minimally invasive surgical treatments without jeopardizing patient safety.
-Technological developments in diagnostic imaging techniques are expected to be a major factor that will contribute towards the development and adoption of new treatment methods.
Up Market Research published a new report titled “Overactive Bladder OAB Therapeutics Market research report which is segmented by Types (Anticholinergic Agents, Beta-3 Adrenoreceptor Agonists), By Applications (Hosptial, Clinci, Other), By Players/Companies Allergan, Astellas Pharma, Hisamitsu Pharmaceutical, Pfizer, Ferring, GlaxoSmithKline, Ion Channel Innovations, Kwang Dong Pharmaceutical, Lanzhou Institute of Biological Products, Merck, ONO Pharmaceutical, Sanofi, Tengion, Teva Pharmaceutical Industries”.
|Report Attributes||Report Details|
|Report Title||Overactive Bladder OAB Therapeutics Market Research Report|
|By Type||Anticholinergic Agents, Beta-3 Adrenoreceptor Agonists|
|By Application||Hosptial, Clinci, Other|
|By Companies||Allergan, Astellas Pharma, Hisamitsu Pharmaceutical, Pfizer, Ferring, GlaxoSmithKline, Ion Channel Innovations, Kwang Dong Pharmaceutical, Lanzhou Institute of Biological Products, Merck, ONO Pharmaceutical, Sanofi, Tengion, Teva Pharmaceutical Industries|
|Regions Covered||North America, Europe, APAC, Latin America, MEA|
|Historical Year||2018 to 2019 (Data from 2010 can be provided as per availability)|
|Number of Pages||218|
|Number of Tables & Figures||153|
|Customization Available||Yes, the report can be customized as per your need.|
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
The market is segmented by Type Anticholinergic Agents, Beta-3 Adrenoreceptor Agonists and By Application Hosptial, Clinci, Other.
Some of the companies that are profiled in this report are:
Overactive Bladder OAB Therapeutics Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
We have studied the Overactive Bladder OAB Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
Reasons to Purchase the Overactive Bladder OAB Therapeutics Market Report:
Some other reports from this category!